Core Insights - The Oncology Institute of Hope and Innovation (TOI) achieved $1.1 million in Medicare savings during Performance Period 2 of the Enhancing Oncology Model (EOM), translating to over $3,500 in savings per patient episode [1][3] - TOI earned maximum quality points for avoiding unnecessary emergency department visits and hospital admissions, driven by its High Value Cancer Care program and 24/7 symptom management support [1][3] - The success in EOM builds on TOI's previous achievements in the Oncology Care Model, where it exceeded quality standards and generated multi-million-dollar savings for Medicare [3] Company Overview - Founded in 2007, TOI specializes in delivering value-based cancer care in community settings, serving approximately 1.9 million patients [4] - The organization operates over 100 clinics and affiliate locations across five states, employing more than 180 clinicians [4] - TOI focuses on providing evidence-based cancer care, including clinical trials and transfusions, traditionally associated with advanced care delivery organizations [4]

Company Overview - The Oncology Institute, Inc. (TOI) is one of the largest value-based oncology groups in the United States, founded in 2007 [3] - TOI provides specialized, evidence-based cancer care to over 1.8 million patients, including clinical trials and transfusions, with over 120 employed clinicians and more than 700 staff across 70 clinic locations [3] Leadership Change - Dr. Jeffrey Langsam has been appointed as the Chief Clinical Officer (CCO) of TOI, effective May 13, 2025 [1] - Dr. Langsam previously held significant roles at Cigna Healthcare and Aetna, bringing extensive experience in oncology and specialty pharmacy to TOI [1][2] Strategic Focus - The appointment of Dr. Langsam is expected to enhance TOI's therapeutic decision-making model and support the growth of its Managed Services Organization (MSO) model [2] - The company is experiencing an acceleration in new value-based partnerships and risk-based contracts, positioning it for continued growth in clinical offerings [2]